RTT NewsA Walk Through Rigel PharmaRTT NewsR548, an oral JAK3 inhibitor for the treatment of transplant rejection and other immune disorders. The compound is currently under phase I studies. The company's preclinical programs include,. * R348, a so…
A Walk Through Rigel PharmaNASDAQ• R548, an oral JAK3 inhibitor for the treatment of transplant rejection and other immune disorders. The compound is currently under phase I studies. The company's preclinical programs include,. * R348, a solu…
Blood tests could replace biopsies by 2016The Province"About 10 per cent of patients have acute kidney rejection," said Tebbutt, a UBC associate professor of medicine. "The problem is you can only spot it once it's happening, and tis…
Economic shot in the arm in BroadmeadowsHume WeeklyAnother plant due to open in 2015 will be used to manufacture Privigen – a plasma-derived immunoglobulin intravenous used to treat everything from primary immune deficiency to blood cancers and transpl…
Orgenesis Meets With The Paul-Ehrlich InstitutePharmaLive.com (press release)The Company believes that converting the diabetic patient's own tissue into insulin-producing cells overcomes the problem of donor shortage and removes the risk of transpl…
Orgenesis Meets With The Paul-Ehrlich InstituteBusiness Wire (press release)The Company believes that converting the diabetic patient's own tissue into insulin-producing cells overcomes the problem of donor shortage and removes the risk of transpla…
Orgenesis Meets With The Paul-Ehrlich InstituteDailyFinanceThe Company believes that converting the diabetic patient's own tissue into insulin-producing cells overcomes the problem of donor shortage and removes the risk of transplant rejection. If …
Trovagene's Foray Into The Conventions Of Molecular DiagnosticsSeeking AlphaFurthermore, adoption of Trovagene's products is not limited to early diagnosis, but according to the company, will include cancer monitoring, detecting transplant reje…
Veloxis Pharmaceuticals announces financial results for the first nine months …Sacramento BeeThe primary endpoint of the study, a composite endpoint (biopsy proven acute rejection, graft failure, loss to follow up or death), will be evaluated after a…
Sir Gus Nossal and Ita Buttrose receive gongs at Research Australia AwardsAustralian Life Scientist… and Marrow Transplantation Laboratory have focused on using preclinical transplant models to dissect the immunological mechanisms of transplant rejec…